Agilent hosts: (1) Early OncNGS consortium data using the Agilent Avida technology, an advanced multiomic target enrichment tool. OncNGS aims to develop an integrated pan cancer assay to be used in future distributed workflows for potential diagnostic, predictive, prognostic and theranostic analysis of liquid biopsies. (2) Data from the DOvEEgene DNA Test, targeting ovarian and endometrial cancer using Agilent’s SureSelect technology, presented by Dr. Ragoussis of McGill.
Note: Products mentioned are for Research Use Only. Not for use in diagnostic procedures.
